| c-erbB-3 proto-oncogene expression in uterine cervical carcinoma. | uterine,cervical, |
| ErbB2/ErbB3 dimer functions as an oncogenic unit to drive breast tumor cell proliferation. | breast, |
| An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival. | skin, |
| ERBB3 knockdown induces cell cycle arrest and activation of Bak and Bax-dependent apoptosis in colon cancer cells. | colorectal, |
| HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells | pancreatic, |
| Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. | None |
| The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner. | None |
| HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. | None |
| the highly regulated nature of HER3 and its role as a dynamic signalling hub linking HER family oncogenes with downstream PI3K/Akt pathway signalling. | None |
| An In Silico Evaluation of Deleterious Nonsynonymous Single Nucleotide Polymorphisms in the ErbB3 Oncogene. | None |
| Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation. | None |
| Data show that proto-oncogene protein ERBB3 knockdown resulted in cell cycle arrest and activation of Bak and Bax-dependent apoptosis. | None |
| Data show that cotreatment with anti-ERBB3 proto-oncogene protein antibody seribantumab and letrozole had increased antitumor activity. | None |
| Data indicate the role of proto-oncogene protein erbB-3 (ErbB3) in hepatitis B virus X protein (HBx)-mediated cell survival. | None |
| Data indicate that clathrin-mediated endocytosis of proto-oncogene protein erbB-3 (ErbB3) is depending on epsin-1. | None |
| Results indicate the feasibility by using a pharmacophore of the small molecular compound VS1 for designing and optimization of proto-oncogene protein erbB-3 (ERBB3) inhibitors. | None |
| our findings provide support for an autocrine signaling loop engaged by oncogenic K-Ras involving ErbB3 that contributes to the dedifferentiation of the intestinal epithelium during tumor initiation and progression. | None |